COMMUNIQUÉS West-GlobeNewswire

Tekton Research Adds Two New Sites to Expand Neuroscience and General Medicine Capabilities in Key U.S. Markets
20/11/2025
Growth strengthens Tekton’s regional density and enhances access to diverse patient populations AUSTIN, Texas, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Tekton Research, a leading multi-site clinical trial organization, today [...]
Omada Health to Participate in Evercore Healthcare Conference
20/11/2025
SAN FRANCISCO, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced that members of senior management will participate in the 8th Annual Evercore [...]
New Men’s Health Research from Progyny Challenges Conventional Beliefs about Fertility Knowledge and Action
20/11/2025
75% of men see fertility as an equal gender topic and acknowledge the connection between fertility health and their overall health, yet only 46% of men with a fertility issue have sought support due to stigma, cost, and [...]
Sharecare selected as exclusive life sciences advertising partner for national point-of-care network CVIEW
20/11/2025
New partnership expands Sharecare’s point-of-care capabilities to more than 3,000 multi-specialty outpatient clinics and lab testing locations, reaching over 2.5 million patients and caregivers monthly ATLANTA, Nov. 20 [...]
RespireRx Pharmaceuticals Inc. CFO and CEO Issue Letter to Stockholders, Stakeholders, Strategic and Potential Strategic Partners and Other Interested Parties
20/11/2025
Glen Rock, N.J., Nov. 20, 2025 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (RespireRx or the Company), and its subsidiaries, EndeavourRx LLC (EndeavourRx) and ResolutionRx Ltd (ResolutionRx), collectively, the [...]
Orbus Therapeutics Highlights Phase 3 STELLAR Clinical Study Results Showing Clinically Meaningful Benefits in Rare Brain Tumor at Society for Neuro-Oncology (SNO) Annual Meeting
20/11/2025
– Updated results based on molecular classification and blinded independent central review demonstrate clinically meaningful survival benefits for patients with recurrent grade 3 astrocytoma who were treated with [...]
SeaStar Medical to Present at Upcoming NobleCon21 Investor Conference
20/11/2025
DENVER, Nov. 20, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and [...]
Navigator Medicines Completes Last Participant Last Visit (LPLV) in Phase 1b Trial of NAV-240, an OX40L and Anti-TNFα Bispecific Antibody for Autoimmune Diseases
20/11/2025
Full Study Results Expected in Q1 2026 Further Clinical Development of NAV-240 in Hidradenitis Suppurativa to Begin in Early 2026 SCOTCH PLAINS, NJ., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Navigator Medicines Inc., a [...]
Life Backup Plan Rolls Out New Version During Medicare Open Enrollment Season and Employer Benefits Review
20/11/2025
New release introduces unparalleled digital medical history and clinical intake capabilities, supporting hospitals, employers, individuals, families, and health insurers—and opens limited Showcase Partner slots for a [...]
Déclaration Intermédiaire Troisième Trimestre : IBA très confiante dans la réalisation de sa guidance 2025, renforcement de la structure de financement
20/11/2025
Louvain-la-Neuve, Belgique, le 20 novembre 2025 - IBA (Ion Beam Applications SA), le leader mondial des technologies d’accélération de particules, publie aujourd'hui la revue de ses activités pour le troisième trimestre [...]
Third quarter 2025 update: IBA is highly confident to meet FY2025 guidance, and strengthens financing structure
20/11/2025
Louvain-la-Neuve, Belgium, 20 November 2025 - IBA (Ion Beam Applications SA), the world leader in particle accelerator technology, shares its business update for the third quarter of 2025. Group Overview Equipment order [...]
Novartis projects +5-6% cc sales CAGR 2025-2030, with long-term growth backed by 30+ potential high-value pipeline assets
20/11/2025
Ad hoc announcement pursuant to Art. 53 LR Mid-term sales guidance rolled forward to +5-6% cc CAGR for 2025-2030, following upgrade of 2024-2029 guidance to +6% cc 1 Peak sales guidance upgraded for Kisqali and Scemblix [...]
Valneva publie ses résultats financiers des neuf premiers mois de 2025 et fait un point sur ses activités
20/11/2025
Chiffre d’affaires de 127,0 millions d’euros contre 116,6 millions d’euros sur les neuf premiers mois de 2024 Trésorerie de 143,5 millions d’euros à fin septembre 2025 Flexibilité financière accrue grâce au succès du [...]
Valneva Reports Nine-Month 2025 Financial Results and Provides Corporate Updates
20/11/2025
Total revenues of €127.0 million compared to €116.6 million in the first nine months of 2024 Cash and cash equivalents of €143.5 million at end of September 2025 Financial flexibility enhanced with successful debt [...]
Burning Rock Reports Third Quarter 2025 Financial Results
20/11/2025
GUANGZHOU, China, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the [...]
IMU Biosciences Appoints Dr. Carlos Paya as Non-Executive Director, Strengthening its Board of Directors
20/11/2025
PRESS RELEASE London, UK, 20 November 2025 — IMU Biosciences (or “the Company”), a biotechnology company decoding the immune system to drive next generation health outcomes, today announced the appointment of Dr. Carlos [...]
Concept Life Sciences Presents New Data Advancing Neuroinflammation and Neurodegeneration Research at Neuroscience 2025
20/11/2025
Three posters highlight advances in inflammasome inhibition, astrocyte neurotoxicity, and myelination models supporting translational drug discovery CHAPEL-EN-LE-FRITH, United Kingdom, Nov. 20, 2025 (GLOBE NEWSWIRE) -- [...]
Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab)
20/11/2025
REYKJAVIK, Iceland and LONDON, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and [...]
Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab)
20/11/2025
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered [...]

Pages